Longfei Mao - Search Results

Year	Number of Results
2013	4
2014	3
2015	1
2019	1
2020	9
2021	8
2022	14
2023	7
2024	8

1

Ferroptosis-related gene signatures in neuroblastoma associated with prognosis.

Chen Y, Li Z, Cao Q, Guan H, Mao L, Zhao M. Chen Y, et al. Among authors: mao l. Front Cell Dev Biol. 2022 Sep 6;10:871512. doi: 10.3389/fcell.2022.871512. eCollection 2022. Front Cell Dev Biol. 2022. PMID: 36147739 Free PMC article.

2

Hydrogen: A Novel Treatment Strategy in Kidney Disease.

Wang B, Li Z, Mao L, Zhao M, Yang B, Tao X, Li Y, Yin G. Wang B, et al. Among authors: mao l. Kidney Dis (Basel). 2022 Jan 12;8(2):126-136. doi: 10.1159/000520981. eCollection 2022 Mar. Kidney Dis (Basel). 2022. PMID: 35527991 Free PMC article. Review.

3

The Relationship among Physical Activity, Intestinal Flora, and Cardiovascular Disease.

Yan Q, Zhai W, Yang C, Li Z, Mao L, Zhao M, Wu X. Yan Q, et al. Among authors: mao l. Cardiovasc Ther. 2021 Oct 12;2021:3364418. doi: 10.1155/2021/3364418. eCollection 2021. Cardiovasc Ther. 2021. PMID: 34729078 Free PMC article. Review.

4

Synthesis and activity of novel indirubin derivatives.

Sun B, Wang J, Liu L, Mao L, Peng L, Wang Y. Sun B, et al. Among authors: mao l. Chem Biol Drug Des. 2021 Mar;97(3):565-571. doi: 10.1111/cbdd.13792. Epub 2020 Sep 21. Chem Biol Drug Des. 2021. PMID: 32914538

5

A constraint-based modelling approach to metabolic dysfunction in Parkinson's disease.

Mao L, Nicolae A, Oliveira MA, He F, Hachi S, Fleming RM. Mao L, et al. Comput Struct Biotechnol J. 2015 Sep 2;13:484-91. doi: 10.1016/j.csbj.2015.08.002. eCollection 2015. Comput Struct Biotechnol J. 2015. PMID: 26504511 Free PMC article. Review.

6

Discovery of Novel 1,2,3-triazole Derivatives as IDO1 Inhibitors.

Hou X, Gong X, Mao L, Zhao J, Yang J. Hou X, et al. Among authors: mao l. Pharmaceuticals (Basel). 2022 Oct 25;15(11):1316. doi: 10.3390/ph15111316. Pharmaceuticals (Basel). 2022. PMID: 36355488 Free PMC article.

7

Design, Synthesis, and Antitumor Activity of Erlotinib Derivatives.

Mao LF, Wang ZZ, Wu Q, Chen X, Yang JX, Wang X, Li YM. Mao LF, et al. Front Pharmacol. 2022 Apr 20;13:849364. doi: 10.3389/fphar.2022.849364. eCollection 2022. Front Pharmacol. 2022. PMID: 35517789 Free PMC article.

8

Discovery of Icotinib-1,2,3-Triazole Derivatives as IDO1 Inhibitors.

Mao LF, Wang YW, Zhao J, Xu GQ, Yao XJ, Li YM. Mao LF, et al. Front Pharmacol. 2020 Sep 30;11:579024. doi: 10.3389/fphar.2020.579024. eCollection 2020. Front Pharmacol. 2020. PMID: 33101032 Free PMC article.

9

The integration of multidisciplinary approaches revealed PTGES3 as a novel drug target for breast cancer treatment.

Yin Q, Ma H, Dong Y, Zhang S, Wang J, Liang J, Mao L, Zeng L, Xiong X, Chen X, Wang J, Zheng X. Yin Q, et al. Among authors: mao l. J Transl Med. 2024 Jan 20;22(1):84. doi: 10.1186/s12967-024-04899-0. J Transl Med. 2024. PMID: 38245717 Free PMC article.

10

Design, synthesis and biological evaluation of erlotinib-based IDO1 inhibitors.

Hou XX, Gong XQ, Mao LF, Sun G, Yang JX. Hou XX, et al. Front Pharmacol. 2022 Aug 10;13:940704. doi: 10.3389/fphar.2022.940704. eCollection 2022. Front Pharmacol. 2022. PMID: 36034879 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

50 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

50 results

Results by year